These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19134026)

  • 1. Haemophilic arthropathy: the importance of the earliest haemarthroses and consequences for treatment.
    Roosendaal G; Jansen NW; Schutgens R; Lafeber FP
    Haemophilia; 2008 Nov; 14 Suppl 6():4-10. PubMed ID: 19134026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of arthropathy in haemophilia: prophylaxis.
    Santagostino E; Mancuso ME
    Haemophilia; 2008 Nov; 14 Suppl 6():16-9. PubMed ID: 19134028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis in adults with haemophilia.
    Hay CR
    Haemophilia; 2007 Sep; 13 Suppl 2():10-5. PubMed ID: 17685918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice.
    Manco-Johnson M
    Haemophilia; 2007 Sep; 13 Suppl 2():4-9. PubMed ID: 17685917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of arthropathy in haemophilia - intensive on-demand treatment, UK perspective.
    Lee CA
    Haemophilia; 2008 Nov; 14 Suppl 6():11-5. PubMed ID: 19134027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.
    Tagliaferri A; Feola G; Molinari AC; Santoro C; Rivolta GF; Cultrera DB; Gagliano F; Zanon E; Mancuso ME; Valdré L; Mameli L; Amoresano S; Mathew P; Coppola A;
    Thromb Haemost; 2015 Jul; 114(1):35-45. PubMed ID: 25855376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for the benefits of prophylaxis in the management of hemophilia A.
    Hoots WK; Nugent DJ
    Thromb Haemost; 2006 Oct; 96(4):433-40. PubMed ID: 17003919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis in people with haemophilia.
    Coppola A; Franchini M; Tagliaferri A
    Thromb Haemost; 2009 Apr; 101(4):674-81. PubMed ID: 19350110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens.
    Collins PW; Björkman S; Fischer K; Blanchette V; Oh M; Schroth P; Fritsch S; Casey K; Spotts G; Ewenstein BM
    J Thromb Haemost; 2010 Feb; 8(2):269-75. PubMed ID: 19943875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing outcomes for patients with severe haemophilia A.
    Pipe SW; Valentino LA
    Haemophilia; 2007 Nov; 13 Suppl 4():1-16; quiz 3 p following 16. PubMed ID: 17822512
    [No Abstract]   [Full Text] [Related]  

  • 12. Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates.
    Nijdam A; Foppen W; De Kleijn P; Mauser-Bunschoten EP; Roosendaal G; van Galen KP; Schutgens RE; van der Schouw YT; Fischer K
    Thromb Haemost; 2016 May; 115(5):931-8. PubMed ID: 26791021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
    Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
    Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations in individualizing prophylaxis in patients with haemophilia A.
    Valentino LA
    Haemophilia; 2014 Sep; 20(5):607-15. PubMed ID: 24712891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose and outcome of care in haemophilia--how do we define cost-effectiveness?
    Fischer K; Van den Berg HM; Thomas R; Kumar S; Poonnoose P; Viswabandya A; Mathews V; Kavitha ML; Bhattacharji S; Srivastava A
    Haemophilia; 2004 Oct; 10 Suppl 4():216-20. PubMed ID: 15479401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.
    Rossbach HC
    Vasc Health Risk Manag; 2010 Mar; 6():59-68. PubMed ID: 20234780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China.
    Tang L; Wu R; Sun J; Zhang X; Feng X; Zhang X; Luke KH; Poon MC
    Haemophilia; 2013 Jan; 19(1):27-34. PubMed ID: 23231016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran.
    Daliri AA; Haghparast H; Mamikhani J
    Int J Technol Assess Health Care; 2009 Oct; 25(4):584-7. PubMed ID: 19845990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevention of joint damage in hemophilic children with early prophylaxis].
    Kreuz W; Escuriola Ettingshausen C; Funk M; Pons S; Schmidt H; Kornhuber B
    Orthopade; 1999 Apr; 28(4):341-6. PubMed ID: 10335528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States.
    Thornburg CD; Carpenter S; Zappa S; Munn J; Leissinger C
    Haemophilia; 2012 Jul; 18(4):568-74. PubMed ID: 22335526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.